Understanding how to improve treatment for young adults with leukemia
Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescentsand Young Adults with Acute Lymphoblastic Leukemia
This study is looking at how well young people with acute lymphoblastic leukemia stick to their chemotherapy medication, 6-mercaptopurine, and how that affects their treatment success, so we can find better ways to help them get the best results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11054646 on NIH RePORTER |
What this research studies
This research investigates the factors affecting the effectiveness of a chemotherapy drug called 6-mercaptopurine (6MP) in adolescents and young adults diagnosed with acute lymphoblastic leukemia (ALL). It aims to identify how well patients adhere to their medication and how healthcare management influences their treatment outcomes. By measuring the levels of a specific metabolite in the patients' DNA, the study seeks to understand the relationship between medication adherence and systemic exposure to 6MP. The findings could help tailor treatment plans to improve survival rates for this age group.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents and young adults aged 15 to 39 who are undergoing treatment for acute lymphoblastic leukemia.
Not a fit: Patients outside the age range of 15 to 39 or those not diagnosed with acute lymphoblastic leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance survival rates for young adults with leukemia.
How similar studies have performed: Previous research has shown that addressing medication adherence can significantly impact treatment outcomes in cancer patients, suggesting that this approach may yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Wolfson, Julie Anna — University of Alabama at Birmingham
- Study coordinator: Wolfson, Julie Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.